Page 5 - Us Market

Pharma stocks rally on lower price erosion, hopes of US generic mkt uptick

Pharma players with a major exposure to US mkt such as Sun Pharma, Lupin, Zydus Life, Dr Reddy's, Aurobindo, Torrent have been outperformers hitting their 52-week highs over the last couple of weeks

Climate laws could price Americans out of EV market, BYD executive warns

BYD Co., China's homegrown company that's now become the world's hottest maker of electric vehicles, has a warning for the US

Dr Reddy's Laboratories launches Regadenoson injection in US market

Dr Reddy's Laboratories Ltd on Friday announced the launch of Regadenoson injection, used as an agent in the imaging of heart muscle to check blood flow, in the US market. Regadenoson injection is supplied as single-dose pre-filled syringes, 0.4mg/5ml (0.08 mg/ml). It is a generic therapeutic equivalent of Lexiscan injection, approved by US Food and Drug Administration (USFDA), Dr Reddy's said in a regulatory filing. The injection is a pharmacologic stress agent for radionuclide myocardial perfusion imaging (MPI) in patients unable to undergo adequate exercise stress. In a separate filing, Dr Reddy's said it has issued a Form 483 with one observation by the USFDA after a routine GMP inspection at its API manufacturing facility (CTO 1) in Bollaram, Hyderabad. "The inspection was conducted from May 1, 2023 to May 5, 2023. We have been issued a Form 483 with one observation, which we will address within the stipulated timeline," the company said. As per USFDA, Form 483 is issued to a

Global Pharma recalls 50,000 tubes of contaminated eye drops in US: USFDA

Global Pharma Healthcare is recalling 50,000 tubes of eye drops in the US market due to bacterial contamination, according to the US Food and Drug Administration (USFDA). As per its latest Enforcement Report, the US health regulator noted that the Chennai-based drug firm is recalling the affected lot of eye lubricant for artificial tears which have been linked to vision loss in the US. The lot has been manufactured by Chennai-based Global Pharma Healthcare and distributed in the US market by New York-based Delsam Pharma, the USFDA said. Stating the reason for recall, the US health regulator said: "FDA analysis found unopened tubes to be contaminated with bacteria." The company initiated the Class I recall on February 24 this year. As per the USFDA, a Class I recall is the most urgent of the three types of FDA recalls and usually pertains to defective products that can cause serious health problems. In February, Global Pharma Healthcare had announced that it is recalling its entir

Multiple triggers likely to help Zydus to continue with its outperformance

New launches in the US, market share gains and steady domestic growth are positives

SVB crisis: How the ripples of the bank's plunge reached foreign shores

Silicon Valley Bank crisis: How has the bank's failure affected other banks and their stocks worldwide? Read more to find out

Pharma firms with India focus preferred as US market concerns grow

Steady outlook and higher returns triggers for companies refining their strategy

HealthKart eyes foray into the US market, plans IPO in next 2-3 years

HealthKart operates two verticals in the Indian market, MuscleBlaze, a sports nutrition brand, and HKVitals, an online health supplement brand

Markets post biggest 1-day loss in nearly 3 months, Sensex ends below 60K

During the week, the Sensex fell 2.4 per cent and the Nifty 2.5 per cent, their worst weekly decline since June 17, 2022

Lupin set to gain market share in US flu season; shares up 6% in 2 sessions

The stock has underperformed peers and the benchmark over the past year

upGrad-backed Harappa launches in US, to upskill 55,000 managers in 3 yrs

Harappa founders cite huge scope as 82% Americans are likely to quit their jobs because of a bad manager, while 44% managers feel they are unprepared for their jobs

Pocket FM announces US foray, crosses $25 mn in annualised revenue run rate

According to Statista, audio OTT market in India is expected to be worth $2.5 billion by 2030

The stealth bull market

With the benefit of hindsight, India's stealth bull market is underpinned by some strong positives. The most important of these is earnings growth across different sectors

Sun Pharma Q2 PAT rises 10.5% YoY to Rs 2,262 crore on robust sales

Gross sales came in at Rs 10,809.2 crore, growing by 13.1% over Q2 last year

Tech Mahindra Q2 net down 4% YoY to Rs 1,285 cr on supply side pressure

Profit was up sequentially, however; Revenue rose 20.7% YoY and 3.3% QoQ, driven by growth in CME segment and the US market

Strong US pipeline, sustained growth trajectory main trigger for Dr Reddy's

Excluding the strong US show led by Revlimid, Q2 was a mixed bag

Q2FY23 preview: Modest revenue growth, Ebitda decline seen in pharma cos

While domestic market demand is strong, analysts expect higher raw material and freight costs to affect business in US, other countries; healthy YoY growth seen in hospitals and diagnostics

Fitch Ratings cuts UK's credit outlook to negative on fiscal risk

The UK's credit outlook was lowered to negative from stable by Fitch Ratings, which cited risk the government's new growth plan could increase the nation's fiscal deficit

Three key trades to watch before another jumbo Fed interest rate hike

Investors bracing for another jumbo Federal Reserve rate hike are focused on a few key trades: betting on deeper inversion in the US yield curve, further losses in stocks and a stronger dollar

Indian equities likely to remain volatile after US Fed chair's speech

On Friday, Fed chair Jerome Powell signaled the US central bank is likely to keep hiking interest rates and keep them elevated to tame inflation.